TG Therapeutics raises 2026 revenue guidance, outlines subcutaneous BRIUMVI timelineNov 9Quarterly updateTG Therapeutics, Inc.ublituximab
TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidanceAug 3Quarterly updateTG Therapeutics, Inc.ublituximab
TG Therapeutics registers two Phase 2 ublituximab trials, in schizophrenia and myasthenia gravisJul 2Weekly roundup, 2 itemsTG Therapeutics, Inc.ublituximab